Before we begin, I'd like to remind listeners that comments made during this call by management will include forward-looking ...

Acrivon Therapeutics, Inc. ("Acrivon” or "Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company ...

Ladies and gentlemen, thank you for joining us today. Welcome to Compugen's Third Quarter 2024 Results Conference Call. At ...

Good morning and welcome to Agenus' third quarter 2024 conference call and webcast. All participants will be in a listen-only ...

A copy of the ESMO poster can be found on the Publications page of ... Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of Section 27A of the ...

Completed Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) and remain on track to submit a BLA ...

About Aptevo Therapeutics Inc. Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for the treatment of cancer. Aptevo is seeking ...

IO Biotech is sponsoring the Phase 2 trial and Merck is supplying pembrolizumab. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, ...

Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ETCompany ParticipantsBill Anderson - Chairman & CEOWolfgang Nickl ...

We recently presented encouraging efficacy and safety data at ESMO on NUC-7738 plus pembrolizumab in patients ... release may contain “forward-looking” statements within the meaning of the Private ...

In September 2024, AstraZeneca presented clinical data showing promising efficacy and a manageable safety profile in trials evaluating rilvegostomig monotherapy in lung cancer and in combination with ...